Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook.
Open original sourceLoading market dashboard
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook.
Open original source